Becoming an Adult

Managing your hemophilia with inhibitors

Managing your hemophilia and inhibitors includes many different aspects—from being sure to treat bleeds quickly to being sure you keep an adequate supply of factor. Your HTC is a wonderful resource to help with all of these issues. Whether it is selecting a therapy, improving your infusion skills, or learning to order medications, the HTC staff can help. Learn more about HTCs—and be sure to connect with a new one if you've moved.

Managing your health

Eating well and exercising regularly are important for anyone with hemophilia and inhibitors. Your HTC can help you figure out the type of exercise which will work best for you. And while it may be more of a challenge to eat nutritiously when you are on your own, it is one of the most important skills you can learn for staying healthy.

Managing your insurance

It is likely that there will be transitions in your insurance as you move into adulthood. SevenSECURE^® can help you understand your needs and identify options so you keep the coverage you need.

Managing your support team

As you move into different life situations—whether it is college or a new job or a new living situation—you need to always make sure that the people around you understand your hemophilia and how they can help you. This includes your friends, neighbors, co-workers, and, if you're in school/college, the school medical team. Your HTC is a key member of your team, so if you move you'll want to find the HTC closest to your new location. You can expand your support team by linking in with groups of people like you—young adults with hemophilia. A number of the hemophilia associations, such as National Hemophilia Foundation (NHF) and Hemophilia Federation of America (HFA), have both local and national groups specifically for young adults.

Managing your time

This means making sure that the time you spend taking care of your hemophilia is as much as you need, but no more than necessary. Things like infusion time, infusion volume, and speed of bleed resolution can all make a difference in how quickly you can get back to what's important—enjoying your life. Find out how NovoSeven^® RT can help you manage your time.

INDICATIONS

NovoSeven^® RT is indicated for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to FVIII or FIX and in patients with acquired hemophilia; prevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B patients with inhibitors to FVIII or FIX and in patients with acquired hemophilia; treatment of bleeding episodes in patients with congenital Factor VII deficiency and prevention of bleeding in surgical interventions or invasive procedures in patients with congenital FVII deficiency.

IMPORTANT SAFETY INFORMATION

The most common side effects in people taking rFVIIa were fever, bleeding, injection site reaction, joint pain, headache, hypertension, hypotension, nausea, vomiting, pain, swelling, and rash.
After taking rFVIIa, some patients have more of a risk of thrombosis, which is when a clot forms in a blood vessel and causes harm. Although the extent of this risk is not known, it is thought to be small. Some patients have conditions that may increase this risk. These include clogged arteries, blood clots that form throughout the body instead of at the place of injury, a type of blood poisoning called septicemia, and crush injury, which is when a body part is crushed or squeezed between heavy or immobile objects. Also, people taking aPCCs/PCCs (activated or nonactivated prothrombin complex concentrates) at the same time that they are taking NovoSeven^® RT may be at increased risk for thrombosis.
People who have ever had a bad reaction to proteins from mice, hamsters, or "bovines" (such as an ox or cow) should consult their physician prior to using NovoSeven^® RT.
Serious adverse events which may or may not have been related to the use of rFVIIa occurred in 14 of the 298 patients in the initial clinical program.
There have been no reports of rFVIIa causing bad reactions to "analgesics" (such as pain killers), "antibiotics" (the drugs used to treat infection), or "sedatives" (sleeping pills or tranquilizers).
Some patients with Factor VII deficiency have developed resistance (antibodies) to Factor VII after treatment with rFVIIa. These patients had been previously treated with human plasma and/or plasma-derived Factor VII.
Use of NovoSeven^® RT with other formulations of rFVIIa is not recommended due to potential dosing errors resulting from different concentrations.

Please click here for NovoSeven^® RT Prescribing Information

Please click here for original NovoSeven^® Prescribing Information

Novo Nordisk is a registered trademark of Novo Nordisk A/S.
NovoSeven is a registered trademark of Novo Nordisk Health Care AG.
© 2008 Novo Nordisk Inc. 135550 June 2008